1. Inhibitors of cullin-RING E3 ubiquitin ligase 4 with antitumor potential.
- Author
-
Wu K, Huynh KQ, Lu I, Moustakim M, Miao H, Yu C, Haeusgen MJ, Hopkins BD, Huang L, Zheng N, Sanchez R, DeVita RJ, and Pan ZQ
- Subjects
- Animals, Antineoplastic Agents chemistry, Apoptosis, Biomarkers, Tumor genetics, Cell Proliferation, Enzyme Inhibitors chemistry, Female, Humans, Leukemia, Myeloid, Acute enzymology, Leukemia, Myeloid, Acute pathology, Mice, Mice, Inbred BALB C, Mice, Nude, Tumor Cells, Cultured, Ubiquitin metabolism, Ubiquitination, Xenograft Model Antitumor Assays, Antineoplastic Agents pharmacology, Biomarkers, Tumor metabolism, Enzyme Inhibitors pharmacology, Gene Expression Regulation, Enzymologic drug effects, Gene Expression Regulation, Neoplastic drug effects, Leukemia, Myeloid, Acute drug therapy, Ubiquitin-Protein Ligases antagonists & inhibitors
- Abstract
Cullin-RING (really intersting new gene) E3 ubiquitin ligases (CRLs) are the largest E3 family and direct numerous protein substrates for proteasomal degradation, thereby impacting a myriad of physiological and pathological processes including cancer. To date, there are no reported small-molecule inhibitors of the catalytic activity of CRLs. Here, we describe high-throughput screening and medicinal chemistry optimization efforts that led to the identification of two compounds, 33-11 and KH-4-43, which inhibit E3 CRL4 and exhibit antitumor potential. These compounds bind to CRL4's core catalytic complex, inhibit CRL4-mediated ubiquitination, and cause stabilization of CRL4's substrate CDT1 in cells. Treatment with 33-11 or KH-4-43 in a panel of 36 tumor cell lines revealed cytotoxicity. The antitumor activity was validated by the ability of the compounds to suppress the growth of human tumor xenografts in mice. Mechanistically, the compounds' cytotoxicity was linked to aberrant accumulation of CDT1 that is known to trigger apoptosis. Moreover, a subset of tumor cells was found to express cullin4 proteins at levels as much as 70-fold lower than those in other tumor lines. The low-cullin4-expressing tumor cells appeared to exhibit increased sensitivity to 33-11/KH-4-43, raising a provocative hypothesis for the role of low E3 abundance as a cancer vulnerability., Competing Interests: Competing interest statement: R.J.D., Z.-Q.P., K.W., K.Q.H., and M.M. are inventors on patent application 63/144,358 submitted by Icahn School of Medicine at Mount Sinai claiming inhibitors of Cullin-RING E3 ubiquitin ligase 4 (CRL4) to treat leukemia and other cancers., (Copyright © 2021 the Author(s). Published by PNAS.)
- Published
- 2021
- Full Text
- View/download PDF